Craft

Aquestive Therapeutics

Stock Price

$5.7

2024-10-29

Market Capitalization

$515.4 M

2024-10-29

Revenue

$44.5 M

FY, 2025

Aquestive Therapeutics Summary

Company Summary

Overview
Aquestive Therapeutics is a pharmaceutical company that is engaged in drug development using PharmFilm technology. Its products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gestalt syndrome; Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder, etc.
Type
Public
Status
Active
Founded
2004
HQ
Warren, NJ, US | view all locations
Website
https://www.aquestive.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Lori J. Braender

    Lori J. Braender, SVP, General Counsel

  • Mark Schobel

    Mark Schobel, Chief Innovation & Technology Officer

    • John Cochran

      John Cochran, Director

      • Ernie Toth

        Ernie Toth, Chief Financial Officer

      Operating MetricsView all

      Doses of Suboxone Produced to Date

      1.1B

      Q1, 2018

      Patents Issued

      200

      Q1, 2018

      Patents (US)

      40

      Q1, 2018

      LocationsView all

      1 location detected

      • Warren, NJ HQ

        United States

        30 Technology Dr S

      Aquestive Therapeutics Financials

      Summary Financials

      Revenue (Q1, 2026)
      $14.4M
      Gross profit (Q1, 2026)
      $11.0M
      Net income (Q1, 2026)
      ($8.1M)
      Cash (Q1, 2026)
      $110.7M
      EBIT (Q1, 2026)
      ($4.2M)
      Enterprise value
      $448.3M

      Footer menu